{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:32:26Z","timestamp":1785843146894,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>About 40\u201350% of patients with amnestic mild cognitive impairment (MCI) are found to have no significant Alzheimer\u2019s pathology based on amyloid PET positivity. Notably, conversion to dementia in this population is known to occur much less often than in amyloid-positive MCI. However, the relationship between MCI and brain amyloid deposition remains largely unknown. Therefore, we investigated the influence of subthreshold levels of amyloid deposition on conversion to dementia in amnestic MCI patients with negative amyloid PET scans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was a retrospective cohort study of patients with amyloid-negative amnestic MCI who visited the memory clinic of Asan Medical Center. All participants underwent detailed neuropsychological testing, brain magnetic resonance imaging, and [<jats:sup>18<\/jats:sup>F]-florbetaben (FBB) positron emission tomography scan (PET). Conversion to dementia was determined by a neurologist based on a clinical interview with a detailed neuropsychological test or a decline in the Korean version of the Mini-Mental State Examination score of more than 4 points per year combined with impaired activities of daily living. Regional cortical amyloid levels were calculated, and a receiver operating characteristic (ROC) curve for conversion to dementia was obtained. To increase the reliability of the results of the study, we analyzed the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) dataset together.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the follow-up period, 36% (39\/107) of patients converted to dementia from amnestic MCI. The dementia converter group displayed increased standardized uptake value ratio (SUVR) values of FBB on PET in the bilateral temporal, parietal, posterior cingulate, occipital, and left precuneus cortices as well as increased global SUVR. Among volume of interests, the left parietal SUVR predicted conversion to dementia with the highest accuracy in the ROC analysis (area under the curve [AUC] = 0.762, <jats:italic>P<\/jats:italic> &lt; 0.001). The combination of precuneus, parietal cortex, and FBB composite SUVRs also showed a higher accuracy in predicting conversion to dementia than other models (AUC = 0.763). Of the results of ADNI data, the SUVR of the left precuneus SUVR showed the highest AUC (AUC = 0.596, <jats:italic>P<\/jats:italic> = 0.006).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings suggest that subthreshold amyloid levels may contribute to conversion to dementia in patients with amyloid-negative amnestic MCI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01035-2","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:11:02Z","timestamp":1657631462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment"],"prefix":"10.1186","volume":"14","author":[{"given":"Hyung-Ji","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsu S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sung","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungyang","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E-Nae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Hyun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hoon","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135.","journal-title":"Science."},{"key":"1035_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/1567205014666170417111859","volume":"15","author":"Y Gao","year":"2018","unstructured":"Gao Y, Tan L, Yu JT, Tan L. Tau in Alzheimer\u2019s disease: mechanisms and therapeutic strategies. Curr Alzheimer Res. 2018;15:283\u2013300.","journal-title":"Curr Alzheimer Res"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","volume":"82","author":"TL Spires-Jones","year":"2014","unstructured":"Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease. Neuron. 2014;82:756\u201371.","journal-title":"Neuron."},{"key":"1035_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1212\/WNL.0000000000007747","volume":"93","author":"GN Bischof","year":"2019","unstructured":"Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning: long way ahead. Neurology. 2019;93:72\u20139.","journal-title":"Neurology."},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1523\/JNEUROSCI.0485-18.2018","volume":"38","author":"SL Leal","year":"2018","unstructured":"Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci. 2018;38:4482\u20139.","journal-title":"J Neurosci"},{"key":"1035_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-019-0557-1","volume":"11","author":"A Rosenberg","year":"2019","unstructured":"Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M. Progression to dementia in memory clinic patients with mild cognitive impairment and normal beta-amyloid. Alzheimers Res Ther. 2019;11:99.","journal-title":"Alzheimers Res Ther"},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"e1809","DOI":"10.1212\/WNL.0000000000006469","volume":"91","author":"ME Farrell","year":"2018","unstructured":"Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology. 2018;91:e1809\u2013e21.","journal-title":"Neurology."},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13195-019-0577-x","volume":"12","author":"SE Kim","year":"2020","unstructured":"Kim SE, Lee B, Park S, Cho SH, Kim SJ, Kim Y, et al. Clinical significance of focal ss-amyloid deposition measured by (18)F-flutemetamol PET. Alzheimers Res Ther. 2020;12:6.","journal-title":"Alzheimers Res Ther"},{"key":"1035_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303\u20138.","journal-title":"Arch Neurol"},{"key":"1035_CR10","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA."},{"key":"1035_CR11","first-page":"e-1","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. Alzheimers Dement. 2013;9:e-1\u201316.","journal-title":"Alzheimers Dement"},{"key":"1035_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","volume":"86","author":"SM Landau","year":"2016","unstructured":"Landau SM, Horng A, Fero A, Jagust WJ. Alzheimer\u2019s Disease Neuroimaging Initiative. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86:1377\u201385.","journal-title":"Neurology."},{"key":"1035_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13195-020-00721-3","volume":"12","author":"A S\u00f6rensen","year":"2020","unstructured":"S\u00f6rensen A, Blazhenets G, Schiller F, Meyer PT, Frings L. Alzheimer Disease Neuroimaging Initiative. Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer\u2019s dementia: a comparison of methods. Alzheimers Res Ther. 2020;12:155.","journal-title":"Alzheimers Res Ther"},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1212\/WNL.0000000000002097","volume":"85","author":"BS Ye","year":"2015","unstructured":"Ye BS, Seo SW, Kim JH, Kim GH, Cho H, Noh Y, et al. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology. 2015;85:1687\u201393.","journal-title":"Neurology."},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"e940","DOI":"10.1212\/WNL.0000000000005124","volume":"90","author":"H Botha","year":"2018","unstructured":"Botha H, Mantyh WG, Graff-Radford J, Machulda MM, Przybelski SA, Wiste HJ, et al. Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology. 2018;90:e940\u2013e6.","journal-title":"Neurology."},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00115-020-00922-z","volume":"92","author":"D G\u00f6r\u00df","year":"2021","unstructured":"G\u00f6r\u00df D, Kilimann I, Dyrba M, Nitsch S, Krause B, Teipel S. LATE: not every dementia is Alzheimer\u2019s disease\u2014discussion of a new disease entity based on a case example : current status of limbic-predominant age-related TDP-43 encephalopathy (LATE). Nervenarzt. 2021;92:18\u201326 German.","journal-title":"Nervenarzt"},{"key":"1035_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/01.jnen.0000225312.11858.57","volume":"65","author":"GA Jicha","year":"2006","unstructured":"Jicha GA, Petersen RC, Knopman DS, Boeve BF, Smith GE, Geda YE, et al. Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment. J Neuropathol Exp Neurol. 2006;65:602\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1035_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2174\/1567205017666201130094259","volume":"17","author":"HJ Kim","year":"2020","unstructured":"Kim HJ, Lee JH, Cheong EN, Chung SE, Jo S, Shim WH, et al. Elucidating the risk factors for progression from amyloid-negative amnestic mild cognitive impairment to dementia. Curr Alzheimer Res. 2020;17:893\u2013903.","journal-title":"Curr Alzheimer Res"},{"key":"1035_CR19","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/ene.14770","volume":"28","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Cheong EN, Jo S, Lee S, Shim WH, Kwon M, et al. The cerebellum could serve as a potential imaging biomarker of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment. Eur J Neurol. 2021;28:1520\u20137.","journal-title":"Eur J Neurol"},{"key":"1035_CR20","doi-asserted-by":"publisher","unstructured":"Kim HJ, Cheong EN, Jo S, Lee S, Shim WH, Kang DW, et al. Early impairment in the ventral visual pathway can predict conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment. Alzheimer Dis Assoc Disord. 2021. https:\/\/doi.org\/10.1097\/WAD.0000000000000457.","DOI":"10.1097\/WAD.0000000000000457"},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394.","journal-title":"J Intern Med"},{"key":"1035_CR22","first-page":"404","volume":"22","author":"RC Petersen","year":"2016","unstructured":"Petersen RC. Mild cognitive impairment. Continuum (Minneap Minn). 2016;22:404\u201318.","journal-title":"Continuum (Minneap Minn)"},{"key":"1035_CR23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.neurobiolaging.2009.09.006","volume":"32","author":"D Lenzi","year":"2011","unstructured":"Lenzi D, Serra L, Perri R, Pantano P, Lenzi GL, Paulesu E, et al. Single domain amnestic MCI: a multiple cognitive domains fMRI investigation. Neurobiol Aging. 2011;32:1542\u201357.","journal-title":"Neurobiol Aging"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1192\/bjp.166.1.4","volume":"166","author":"JE Cooper","year":"1995","unstructured":"Cooper JE. On the publication of the Diagnostic and Statistical manual of mental disorders: fourth edition (DSM-IV). Br J Psychiatry. 1995;166:4\u20138.","journal-title":"Br J Psychiatry"},{"key":"1035_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000339367","volume":"33","author":"CG Schipke","year":"2012","unstructured":"Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2012;33:416\u201322.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1035_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13\u201326.","journal-title":"Clin Transl Imaging"},{"key":"1035_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00259-019-04595-y","volume":"47","author":"HJ Son","year":"2020","unstructured":"Son HJ, Oh JS, Oh M, Kim SJ, Lee JH, Roh JH, et al. The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases. Eur J Nucl Med Mol Imaging. 2020;47:332\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"key":"1035_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/156720511794604552","volume":"8","author":"C Marra","year":"2011","unstructured":"Marra C, Ferraccioli M, Vita MG, Quaranta D, Gainotti G. Patterns of cognitive decline and rates of conversion to dementia in patients with degenerative and vascular forms of MCI. Curr Alzheimer Res. 2011;8:24\u201331.","journal-title":"Curr Alzheimer Res"},{"key":"1035_CR30","doi-asserted-by":"publisher","first-page":"19024","DOI":"10.1038\/s41598-019-54204-z","volume":"9","author":"K Blennow","year":"2019","unstructured":"Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, et al. Predicting clinical decline and conversion to Alzheimer\u2019s disease or dementia using novel Elecsys A\u03b2(1-42), pTau and tTau CSF immunoassays. Sci Rep. 2019;9:19024.","journal-title":"Sci Rep"},{"key":"1035_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WAD.0000000000000406","volume":"35","author":"XV Nguyen","year":"2021","unstructured":"Nguyen XV, Candemir S, Erdal BS, White RD, Prevedello LM. Predicting mental decline rates in mild cognitive impairment from baseline MRI volumetric data. Alzheimer Dis Assoc Disord. 2021;35:1\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1035_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.12779\/dnd.2019.18.3.77","volume":"18","author":"SH Kang","year":"2019","unstructured":"Kang SH, Park YH, Lee D, Kim JP, Chin J, Ahn Y, et al. The cortical neuroanatomy related to specific neuropsychological deficits in Alzheimer\u2019s continuum. Dementia Neurocogn Disord. 2019;18:77\u201395.","journal-title":"Dementia Neurocogn Disord"},{"key":"1035_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fninf.2018.00064","volume":"12","author":"T Funck","year":"2018","unstructured":"Funck T, Larcher K, Toussaint PJ, Evans AC, Thiel A. APPIAN: automated pipeline for PET image analysis. Front Neuroinform. 2018;12:64.","journal-title":"Front Neuroinform"},{"key":"1035_CR34","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00259-019-04663-3","volume":"47","author":"JP Kim","year":"2020","unstructured":"Kim JP, Kim J, Kim Y, Moon SH, Park YH, Yoo S, et al. Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes. Eur J Nucl Med Mol Imaging. 2020;47:1971\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1035_CR35","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2967\/jnumed.116.187351","volume":"58","author":"S Bullich","year":"2017","unstructured":"Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, et al. Optimal reference region to measure longitudinal amyloid-\u03b2 change with 18F-florbetaben PET. J Nucl Med. 2017;58:1300\u20136.","journal-title":"J Nucl Med"},{"key":"1035_CR36","doi-asserted-by":"publisher","first-page":"14950","DOI":"10.1038\/s41598-020-70978-z","volume":"10","author":"SH Cho","year":"2020","unstructured":"Cho SH, Choe YS, Park S, Kim YJ, Kim HJ, Jang H, et al. Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Sci Rep. 2020;10:14950.","journal-title":"Sci Rep"},{"key":"1035_CR37","doi-asserted-by":"publisher","first-page":"7364","DOI":"10.1523\/JNEUROSCI.0639-16.2016","volume":"36","author":"J Sepulcre","year":"2016","unstructured":"Sepulcre J, Schultz AP, Sabuncu M, Gomez-Isla T, Chhatwal J, Becker A, et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J Neurosci. 2016;36:7364\u201374.","journal-title":"J Neurosci"},{"key":"1035_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1035_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312\u201339.","journal-title":"Cell."},{"key":"1035_CR40","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun. 2020;11:2612.","journal-title":"Nat Commun"},{"key":"1035_CR41","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27:871\u201381.","journal-title":"Nat Med"},{"key":"1035_CR42","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease. Sci Adv 2020;6:eaaz2387.","DOI":"10.1126\/sciadv.aaz2387"},{"key":"1035_CR43","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00259-019-04669-x","volume":"47","author":"JB Pereira","year":"2020","unstructured":"Pereira JB, Harrison TM, La Joie R, Baker SL, Jagust WJ. Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. Eur J Nucl Med Mol Imaging. 2020;47:2155\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1035_CR44","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00259-020-04773-3","volume":"47","author":"MS Baek","year":"2020","unstructured":"Baek MS, Cho H, Lee HS, Choi JY, Lee JH, Ryu YH, et al. Temporal trajectories of in vivo tau and amyloid-\u03b2 accumulation in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47:2879\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1035_CR45","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/brain\/awab114","volume":"144","author":"D Berron","year":"2021","unstructured":"Berron D, Vogel JW, Insel PS, Pereira JB, Xie L, Wisse LEM, et al. Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain. 2021;144:2771\u201383.","journal-title":"Brain."},{"key":"1035_CR46","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/156720512801322546","volume":"9","author":"JA Mortimer","year":"2012","unstructured":"Mortimer JA. The Nun Study: risk factors for pathology and clinical-pathologic correlations. Curr Alzheimer Res. 2012;9:621\u20137.","journal-title":"Curr Alzheimer Res"},{"key":"1035_CR47","doi-asserted-by":"publisher","first-page":"e2201","DOI":"10.1212\/WNL.0000000000011833","volume":"96","author":"SH Kang","year":"2021","unstructured":"Kang SH, Kim ME, Jang H, Kwon H, Lee H, Kim HJ, et al. Amyloid positivity in the Alzheimer\/subcortical-vascular spectrum. Neurology. 2021;96:e2201\u2013e11.","journal-title":"Neurology."},{"key":"1035_CR48","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3233\/JAD-150832","volume":"54","author":"Y Noh","year":"2016","unstructured":"Noh Y, Seo SW, Jeon S, Lee JM, Kim JS, Lee JH, et al. The role of cerebrovascular disease in amyloid deposition. J Alzheimers Dis. 2016;54:1015\u201326.","journal-title":"J Alzheimers Dis"},{"key":"1035_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neurobiolaging.2017.03.010","volume":"55","author":"YJ Hong","year":"2017","unstructured":"Hong YJ, Kim CM, Kim JE, Roh JH, Kim JS, Seo SW, et al. Regional amyloid burden and lacune in pure subcortical vascular cognitive impairment. Neurobiol Aging. 2017;55:20\u20136.","journal-title":"Neurobiol Aging"},{"key":"1035_CR50","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/acn3.51135","volume":"7","author":"OL Lopez","year":"2020","unstructured":"Lopez OL, Kofler J, Chang Y, Berman SB, Becker JT, Sweet RA, et al. Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients. Ann Clin Transl Neurol. 2020;7:1546\u201356.","journal-title":"Ann Clin Transl Neurol"},{"key":"1035_CR51","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.nbd.2017.04.012","volume":"103","author":"SA Davis","year":"2017","unstructured":"Davis SA, Gan KA, Dowell JA, Cairns NJ, Gitcho MA. TDP-43 expression influences amyloid\u03b2 plaque deposition and tau aggregation. Neurobiol Dis. 2017;103:154\u201362.","journal-title":"Neurobiol Dis"},{"key":"1035_CR52","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, Sch\u00f6ll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8:1214.","journal-title":"Nat Commun"},{"key":"1035_CR53","volume":"12","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, et al. Topographical distribution of A\u03b2 predicts progression to dementia in A\u03b2 positive mild cognitive impairment. Alzheimers Dement (Amst). 2020;12:e12037.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1035_CR54","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1038\/s41598-018-23676-w","volume":"8","author":"BS Ye","year":"2018","unstructured":"Ye BS, Kim HJ, Kim YJ, Jung NY, Lee JS, Lee J, et al. Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: a three-year longitudinal study. Sci Rep. 2018;8:5557.","journal-title":"Sci Rep"},{"key":"1035_CR55","doi-asserted-by":"crossref","unstructured":"Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid \u03b2 and tau in Alzheimer\u2019s disease: implications for primary prevention. Brain Commun 2020;2:fcaa007.","DOI":"10.1093\/braincomms\/fcaa007"},{"key":"1035_CR56","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.biopsych.2009.08.024","volume":"67","author":"YI Sheline","year":"2010","unstructured":"Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584\u20137.","journal-title":"Biol Psychiatry"},{"key":"1035_CR57","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jnnp.2004.045567","volume":"77","author":"OL Lopez","year":"2006","unstructured":"Lopez OL, Becker JT, Jagust WJ, Fitzpatrick A, Carlson MC, DeKosky ST, et al. Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry. 2006;77:159\u201365.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1035_CR58","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509\u201317.","journal-title":"Arch Neurol"},{"key":"1035_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13195-016-0204-z","volume":"8","author":"L Saint-Aubert","year":"2016","unstructured":"Saint-Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A. Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8:38.","journal-title":"Alzheimers Res Ther"},{"key":"1035_CR60","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1097\/RLU.0000000000002791","volume":"44","author":"V Baghel","year":"2019","unstructured":"Baghel V, Tripathi M, Parida G, Gupta R, Yadav S, Kumar P, et al. In vivo assessment of tau deposition in Alzheimer disease and assessing its relationship to regional brain glucose metabolism and cognition. Clin Nucl Med. 2019;44:e597\u2013601.","journal-title":"Clin Nucl Med"},{"key":"1035_CR61","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.25739","volume":"87","author":"M Scarioni","year":"2020","unstructured":"Scarioni M, Gami-Patel P, Timar Y, Seelaar H, van Swieten JC, Rozemuller AJM, et al. Frontotemporal dementia: correlations between psychiatric symptoms and pathology. Ann Neurol. 2020;87:950\u201361.","journal-title":"Ann Neurol"},{"key":"1035_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/neup.12597","volume":"40","author":"T Kon","year":"2020","unstructured":"Kon T, Tomiyama M, Wakabayashi K. Neuropathology of Lewy body disease: clinicopathological crosstalk between typical and atypical cases. Neuropathology. 2020;40:30\u20139.","journal-title":"Neuropathology."},{"key":"1035_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12939","volume":"31","author":"S Agrawal","year":"2021","unstructured":"Agrawal S, Yu L, Kapasi A, James BD, Arfanakis K, Barnes LL, et al. Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change and microvascular pathologies in community-dwelling older persons. Brain Pathol. 2021;31:e12939.","journal-title":"Brain Pathol"},{"key":"1035_CR64","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/jnnp-2020-324306","volume":"92","author":"S Halbgebauer","year":"2020","unstructured":"Halbgebauer S, Oeckl P, Steinacker P, Yilmazer-Hanke D, Anderl-Straub S, von Arnim C, et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2020;92:349\u201356.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01035-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:16:19Z","timestamp":1657631779000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01035-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01035-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Asan Medical Center, Republic of Korea (#2019-0738). The informed consent was waived due to the retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}